The American Society of Addiction Medicine (ASAM) has released interim guidance for treating alcohol use disorder (AUD) and managing ambulatory alcohol withdrawal during the pandemic, in addition to updating its withdrawal management guidelines.
During this presentation, we will be joined by two practicing addiction specialists who contributed to those guidelines and will share their experience applying them within their own practices:
-Anika Alvanzo, MD, MS, DFASAM, FACP, Eastern Region Medical Director, Pyramid Healthcare
-Brian Hurley, MD, MBA, DFASAM, Director of Addiction Medicine, Los Angeles County Department of Health Services
Participant will be able to:
-Understand the process for development of the ASAM Alcohol Withdrawal Management Guidelines
-Describe assessment and risk stratification of patients with alcohol withdrawal
-Discuss pharmacotherapy for alcohol withdrawal in the ambulatory setting
-Discuss the use of gabapentin and carbamazepine for ambulatory alcohol withdrawal management
-Describe a protocol of escalation from gabapentin or carbamazepine to benzodiazepines and/or phenobarbital is clinically appropriate
-Explain how medications for alcohol withdrawal syndrome can be operationalized for underresourced settings and offered to people experiencing homelessness in the context of the COVID-19 pandemic.
AMA Credit Designation Statement:
The American Society of Addiction Medicine designates this live activity for a maximum of 3 AMA PRA Category 1 Credit (s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
1 AMA PRA Category 1 Credits™ available for each date: September 22, October 22 and November 19.
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The American Society of Addiction Medicine